Displaying 1 - 1 of 1
| Active Ingredient | BICALUTAMIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Bicalutamide is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression. |
| Caution | Consider periodic liver function tests. Constipation, dyspepsia, flatulence, pruritus, asthenia, alopecia, jaundice, dry skin, hot flashes, gynaecomastia and/or breast pain and photosensitiv More ... |
| Dose Range |
50mg once daily in conjunction with a gonadotropin-releasing hormone (GnRH) analog. 150 mg once a day as monotherapy |
| Drug Interactions |
Bicalutamide is an inhibitor of CYP 3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Caution should be exercised with the co-administration of bicalutamide with compounds such a More ... |
| Pregnancy | Bicalutamide is contraindicated in females and should not be used |
| Breast Feeding | Bicalutamide is contraindicated in females and should not be used during breast- More ... |